Natco Pharma Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ro07lb7lu7h0dtvwy24ue7c2.pdf

Key Takeaways


Revlimid: The Quarter's Defining Dynamic

Rajeev Nannapaneni: "I can't predict the pricing environment a few years down the line. I can't answer that question. Sorry."

Subsidiaries & International Expansion

Rajeev Nannapaneni: "The future of the business is the subs."

R&D & Pipeline Strategy

Rajeev Nannapaneni: "I think the question that NATCO is facing is -- what do we do with our surplus, right? And I think I have decided that I'll use the surplus for spending money on bio studies and new exhibit batches."

Base Business & Profitability

Rajeev Nannapaneni: "In a multi-generic source, there's no money. It's the honest truth."

Agro & Crop Protection


Domestic Business & Capital Allocation

Rajeev Nannapaneni: "Hopefully, I'll able to close something this year. Yes, hopefully I'll able to close something. I mean, I've been saying that for the last 2 years. I know I've not delivered. So I'll be honest with you."

Guidance & Commitments

CommitmentSpecificsTimeline
Revlimid volume sell-through75% of current allocation remains; expected to sell in June quarter with spill into SeptemberQ1–Q2 FY24
Agro inventory liquidation~INR100–110 crores to be liquidated in Kharif seasonJune and September quarters
R&D spendingMore than INR300 crores, ~10% of revenues, 50% higher than last yearFY24
Subsidiary growth15–20% growth led by new launchesFY24
API business growth20–25% internal projectionFY24
Domestic organic growth8–10% organic; 20–25% including acquisitionsFY24
Product filings (key markets)U.S.: 8–10, Canada: 8–10, Brazil: 8–10FY24
FTF/niche filingsAnother 8–10 targetedFY24
India product launchesAbout 10 productsFY24
Agro revenue targetINR150-plus crores, targeting INR200 croresFY24
Base business profitabilityINR100 crores quarterly PATNext 1–2 years
DASH front-end benefitOwn front end to start contributingNext 1–2 years
Agri pipeline launches5–6 first-time indigenized productsNext 2 years

Key Metrics

MetricQ4 FY23
Consolidated total revenue₹2,811.7 cr for FY23, growth of ~37.6% YoY
Consolidated net profit₹715.3 cr for FY23, versus ₹170 cr last year
Q4 consolidated net revenue₹926.9 cr, versus ₹610.6 cr in Q4 last year
Q4 consolidated profit₹275.8 cr, versus a loss of ₹50.5 cr in Q4 last year
Domestic business run rate~₹100 cr per quarter
Domestic business growth target8% to 10% organic, acquisition plus organic target 20% to 25%
API business growth projection20% to 25% for FY24
Subsidiaries revenue contribution~₹555 cr gross, net ₹375 cr after deducting inter-company sales
Subsidiaries Q4 profit (PBT)₹28.97 cr
Canada subsidiary revenue~CAD 4 cr
Brazil subsidiary revenue~2.1 cr
Crop protection revenue₹40 cr in FY23, projection of ₹150-plus cr for FY24
Agro inventory~₹100 cr to ₹110 cr
Revlimid allocation sold~25% of allocated quantity sold, 75% remaining
R&D spend~8% of revenue in FY23, guidance of ~10% for FY24
Cash balance₹1,089 cr as of March 31, 2023
Borrowings₹165 cr total, of which ₹95 cr is foreign bill discounting, ₹70 cr actual bank borrowing
Buyback~35 lakh shares bought back, equity reduced from ₹18.25 cr to ₹17.91 cr
One-time charge to raw material supplier₹50 cr for first-to-file success payment
Intangible asset purchase₹50 cr, goodwill on acquisition of DASH